The FDA has approved the first generic formulation of capecitabine (Xeloda), an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer (mCRC) and ...

Please provide your email address to receive an email when new articles are posted on . Overall survival of patients with metastatic colorectal cancer who completed 16 weeks of first-line chemotherapy ...

The FDA has approved neratinib (Puma Biotechnology), a kinase inhibitor, in combination with capecitabine, for the treatment of adult patients with advanced or metastatic human epidermal growth factor ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of capecitabine, having considered evidence on the nature of gastric cancer and the value placed on the ...

Colorectal cancer (CRC) is one of the most common tumours worldwide, with approximately 1 million new cases diagnosed in 2000 accounting for over 500 000 deaths. At some stage during the course of the ...

Please provide your email address to receive an email when new articles are posted on . Capecitabine maintenance therapy significantly prolonged PFS among patients with newly diagnosed metastatic ...

The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and ...

Systemic adjuvant or neoadjuvant chemotherapy, biologic, and hormone therapies have improved outcomes of patients with early-stage breast cancer. However, a substantial number of patients with ...

Review the side-effects of Capecitabine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

The introduction of newer cytotoxic drugs such as oxaliplatin and irinotecan as well as the development of targeted agents including inhibitors of the epidermal growth factor receptor (ie, cetuximab ...

We reported previously (Jan. 3, 2008, issue) 1 that capecitabine and oxaliplatin are as effective as infused fluorouracil and cisplatin, respectively, in patients with previously untreated ...